To our knowledge, this is the first study to show that OSBPL3, which is overexpressed by DNA copy number gain and promoter hypomethylation, affects not only the malignant phenotype of GC but also the clinical outcome of GC patients. Here, OSBPL3 is linked to gastric cancer.